9. Lampl C, Yazdi K: Central pontine myelinolysis. A study in scarlet-convalescent plasma for severe influenza* I n patients with influenza disease, treatment with currently available antivirals (e.g., oseltamivir) decreases mortality (1, 2) but mortality remains unacceptably high in patients with severe disease caused by 2009 pandemic H1N1 (10%-17%) (3, 4) and H5N1 (40%) (2) . Additionally, the emergence of widespread oseltamivir or adamantane resistance to circulating influenza strains or resistance developing during treatment, the reports of dual oseltamivir-adamantane resistance, and person-to-person transmission of these viruses highlight the need for new approaches and better treatments (5) (6) (7) (8) .
Passive immunotherapy with influenza strain-specific convalescent plasma (containing polyclonal antibodies) has been proposed as a potential treatment option for serious influenza disease (9, 10) .
Case reports in H5N1 influenza have described dramatic defervescence and cessation of viral shedding after administration of convalescent plasma (11) . After the emergence of pandemic H1N1, Hung et al conducted a prospective cohort study in which seriously ill pandemic H1N1 patients in Hong Kong were treated with 500 mL of convalescent plasma with hemagglutination (HAI) titer of Ն1:160 in addition to standard care vs. standard care alone (12) . Although the cohort design limits the interpretation of this study, the mortality rate between the treatment and control group was reported to decrease by 34% (20.0% vs. 54.8%; p ϭ .01). Additionally, respiratory tract viral load and cytokine levels were lower in the treatment group on days 3, 5, and 7 (p Ͻ .05).
In this issue of Critical Care Medicine, Rockman et al (13) provide additional important insights into the potential efficacy of passive immunotherapy (manuscript citation) in treating highly pathogenic avian influenza. Rockman et al using a lethal challenge model infused 10 mL of convalescent serum with a HAI titer of 1:128 into young ferrets and then challenged them with 10 6 EID 50 of highly virulent A/Vietnam/1203/2004 H5N1. Euthanasia was scheduled at 10% body weight loss within 7 days of virus exposure or exhibition of signs consistent with involvement of other organ systems. Animals received H5N1 convalescent serum 24 hrs before or 24 hrs or 72 hrs after challenge (or control H3N2 serum or phosphate-buffered saline 24 hrs before challenge). The infusion of H5N1 convalescent serum in the treatment animals resulted in a HAI of 1:4 -1:8. Although no control animals survived, 100% (four of four) of animals administered H5N1 convalescent serum infused 24 hrs before viral challenge, 75% (three of four) infused 24 hrs after, and 25% (one of four) infused 72 hrs after survived. Additionally, nasal viral titers in the treatment groups tended to be much lower than in controls at the time points tested. The study design of Rockman et al (the low 1:4 -1:8 HAI titers achieved in the treated animals, the large infectious dose, and the euthanasia of animals at a conservative 10% weight loss) may have masked the full effect and analysis of convalescent plasma. However, this study suggests that convalescent plasma can be a beneficial treatment for highly pathogenic avian influenza at "low doses" and adds significantly to the literature on this topic.
In a comparable high lethality model using oseltamivir as the intervention, Govorkova et al (14) infected young ferrets with 10 2 EID 50 A/Vietnam/1203/2004 H5N1 (compared to 10 6 EID 50 in the current article). They administered 10 or 25 mg/kg/day of oseltamivir twice daily for 5 days, starting 24 hrs after challenge. Euthanasia was scheduled for animals that had both severe disease and that lost 25% of body weight. They reported that the oseltamivir twice daily 10 mg/kg/day group (resulting in a comparable area under the curve drug level to a licensed dose in humans) experienced 0% (zero of three) survival, a maximal weight loss of 22%, and nasal viral shedding on day 3 of 4 log 10 EID 50 . The twice daily 25 mg/ kg/day group experienced 100% (zero of three) survival, a maximal weight loss of 13%, and nasal viral shedding on day 3 of 3 log 10 EID 50 . This is compared to 75% (three of four) survival, a weight loss of 13%, and nasal viral shedding on day 3 of 2 log 10 EID 50 in the current article. Although these were not direct comparative arms in a single study, the data suggest that administering a single dose of convalescent plasma with a moderate HAI titer may be as or more effective than oseltamivir.
The true clinical question is not if convalescent plasma is as effective as oseltamivir in the treatment of highly pathogenic avian influenza or seasonal influenza. Convalescent plasma will not supplant small molecules in the treatment of uncomplicated influenza. The clinical need is to modify the outcomes in severe disease-new therapeutic approaches that are synergistically or additively beneficial with the standard of care are desirable. To test this hypothesis, the National Institute of Allergy and Infectious Diseases is currently conducting a randomized multicentered clinical trial to test the efficacy of immune plasma to treat serious type A influenza infections (ClinicalTrials.gov, identifier: NCT01052480).
Many questions remain about convalescent plasma-how much of severe disease is attributable to viral replication vs. inflammation, what is the target human avian influenza in recipients, can plasma help to address situations in which resistance arises, and so on. More definitive animal and human studies are still needed to answer these questions. However, plasma therapy is an approach worth fully exploring.
John (1) describe the increasingly common practice of assigning equal credit among two or more authors of papers submitted to leading journals of critical care medicine. As readers of these important and prestigious journals know, the practice of assigning equal credit is now commonplace. Wang and colleagues have nicely characterized the practice and its growth.
The practice is not only pervasive but increasing. The annual statistics ( Table 1 in the Wang et al article) suggest that the practice was occurring but hit an inflection around [2005] [2006] , at which point a steady rise occurs. Furthermore, while the assignment of equal credit can occur across any positions in the authorship roster, the most common positions are the first and second, essentially yielding a pair of first authors for the majority of papers in which the practice occurred.
Why does order matter? As Zuckerman (2) pointed out in her seminal 1968 study of the topic, every social institution provides for the evaluation of role performance. In science, that evaluation is founded on peer review. Before the Second World War, a scientist might have had many assistants but the publications were nearly always issued under a single name. There was never doubt as to whose work was being reviewed. The Manhattan Project and other wartime efforts brought teams of scientists together for a common purpose. However, manuscripts and authorship took a back seat to security and survival.
As the postwar social organization of science became more complex, the scientific community was beset with a nowfamiliar problem: an evolving functional requirement that science be collaborative and systems that bestow honors, prizes, and tenure on individuals. Thus the patterns of name ordering on papers emerged as an adaptive mechanism to address this specific malintegration of the social organization of research with the rewards of that research. Whether the name-ordering mechanism is effectual or ineffectual in conveying responsibility for
